---
title: "Piper Sandler Sticks to Its Buy Rating for Immuneering (IMRX)"
description: "Bratzel covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Argenx Se, and Ardelyx. According to TipRanks, Bratzel has an average return of 52.0% and a 68.52% success rat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259041359.md"
published_at: "2025-09-26T10:37:13.000Z"
---

# Piper Sandler Sticks to Its Buy Rating for Immuneering (IMRX)

> Bratzel covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Argenx Se, and Ardelyx. According to TipRanks, Bratzel has an average return of 52.0% and a 68.52% success rate on recommended stocks. Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $15.20, implying a 90.00% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $10.00 price target.

Bratzel covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Argenx Se, and Ardelyx. According to TipRanks, Bratzel has an average return of 52.0% and a 68.52% success rate on recommended stocks.

Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $15.20, implying a 90.00% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $10.00 price target.

### Related Stocks

- [IMRX.US - Immuneering](https://longbridge.com/en/quote/IMRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuneering Director Thomas J. Schall Reports Acquisition of Common Shares | Thomas J. Schall, Director of Immuneering Corporation, has reported the acquisition of Class A common shares of the comp | [Link](https://longbridge.com/en/news/273098166.md) |
| Top Immuneering Executive Makes Bold Move With Fresh Stock Purchase | Immuneering's Chief People Officer, Leah R. Neufeld, purchased 2,626 shares of the company's stock, valued at $10,897, i | [Link](https://longbridge.com/en/news/272771964.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/en/news/275622408.md) |
| Jorie AI Shares a Live Case Study on the Inevitable Future of Healthcare AI at ViVE 2026 | Jorie AI showcased its autonomous healthcare AI solutions at ViVE 2026, emphasizing the need for AI to operate effective | [Link](https://longbridge.com/en/news/275497445.md) |
| ZAWYA-PRESSR: Healthcare leaders call for greater strategic alignment between capital investment and health system strategy at WHX | Global healthcare leaders gathered at the World Health Expo (WHX) to discuss the need for strategic alignment between ca | [Link](https://longbridge.com/en/news/275449733.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.